Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NS87
UPID:
KIF15_HUMAN
Alternative names:
Kinesin-like protein 2; Kinesin-like protein 7; Serologically defined breast cancer antigen NY-BR-62
Alternative UPACC:
Q9NS87; Q17RV9; Q69YL6; Q96JX7; Q9H280
Background:
Kinesin-like protein KIF15, also known as Kinesin-like protein 2, Kinesin-like protein 7, and Serologically defined breast cancer antigen NY-BR-62, plays a pivotal role in mitotic spindle assembly. This plus-end directed kinesin-like motor enzyme is crucial for proper cell division.
Therapeutic significance:
Linked to Braddock-Carey syndrome 2, characterized by microcephaly, congenital thrombocytopenia, and facial dysmorphisms, KIF15's study could lead to novel treatments for this autosomal recessive disease.